Quoin Pharmaceuticals, Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| QNRX | VRCA | FBIO | HIND | CTXR | PVLA | |
|---|---|---|---|---|---|---|
| Market cap | 20.95M | 68.89M | 70.37M | 14.11M | 13.53M | 1.94B |
| P/E (TTM) | — | — | 0.8 | 1.1 | — | — |
| Forward P/E | -1.4 | -2.7 | -1.2 | — | -0.3 | -17.9 |
| Price/book | 0.5 | 16.0 | 0.4 | 2.3 | 0.2 | 8.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −68.97% | −2.43% | −22.71% | −62.08% | −62.08% | +82.78% |
| Today | −3.11% | −2.43% | −1.17% | −3.83% | −1.32% | −3.16% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All QNRX news ›Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
The Manila Times - Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome - Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use…
Quoin Pharmaceuticals Announces Peer-Reviewed Publication Introducing QRX003 and Reporting Positive Pediatric Compassionate-Use Results in Netherton Syndrome
Quoin Pharmaceuticals publishes a paper on QRX003 for Netherton Syndrome, detailing positive pediatric case report outcomes. QRX003 is an investigational topical serine protease inhibitor lotion aimed at treating Netherton Syndrome and…
From articles in the 4Search news index.